Low CV Risk, Ages 25-44 & CV/non-CV Outcomes, Ages 65+

描述（由申请人提供）：背景：已经证明，低风险（LR），即，国家政策建议和2010年目标中界定的所有可衡量的主要风险因素达到有利水平（SBP/DBP <120/<80 mmHg，血清总胆固醇<200 mg/dl，BMI<25 kg/m2，不吸烟，无糖尿病，无MI病史），临床CHD/CVD少见（地方病，而不是流行病），估计寿命增加了几年，老年人的医疗保健费用大大减少。重大的知识差距仍有待弥合，特别是在青年和中年早期低风险与实现无CVD健康老龄化的相关性方面，即，不仅临床上更少，而且非侵入性可检测的亚临床CVD也更少，可能与CVD相关的炎性标记物的更有利水平，以及更高水平的身体表现和身体功能。没有关于这些问题的数据。目的：概述：以有效且具有成本效益的方式扩展芝加哥心脏协会（CHA）研究数据库的新数据，以进一步为了解年轻人/中年早期低风险（LR）的数十年后果做出重大贡献，特别是其与实现老年人无创检测亚临床CHD/CVD的相关性，CHD/CVD风险的炎症标志物，以及身体表现和功能的损害--在男女和不同种族的社会经济地位阶层中，包括已经长寿的人（75岁以上）。为了实现目标（一般和具体），将在2006-2009年对1967-73年25-44岁CHA队列基线的加权随机样本-低风险（n=600）和非低风险（n=900）-进行检查，年龄为65-79岁。具体目标：评估基线LR状态（25-44岁）与以下各项的长期关系：1）65-79岁时亚临床动脉粥样硬化疾病的存在和程度; 2）65-79岁时CVD相关炎症标志物的水平; 3）65-79岁时客观测量的身体表现/功能水平。4)确定当前亚临床动脉粥样硬化疾病和炎症标志物在解释年轻时LR特征与老年时身体表现/功能相关性中的作用。重要性：从拟议的研究中获得的预期新数据可以用来澄清和通报实现2010年健康人的两个主要目标的战略优先事项，即“提高健康生活的质量和年数”和“消除健康差距。"

DESCRIPTION (provided by applicant): Background: It has been demonstrated that with low risk (LR), i.e., favorable levels of all readily measurable major risk factors, as defined in national policy recommendations and objectives for 2010 (SBP/DBP <120/<80 mmHg, serum total cholesterol <200 mg/dl, BMI<25 kg/m2, no smoking, no diabetes, no MI history), clinical CHD/CVD is rare (endemic, not epidemic), estimated longevity is increased by several years, and medical care costs in older persons are sizably reduced. Significant knowledge gaps remain to be closed, especially on the relevance of low risk in young adulthood and early middle age for achieving CVD-free healthy aging, i.e., not only less clinical but also less non- invasively detectable subclinical CVD, more favorable levels of inflammatory markers possibly related to CVD, and higher levels of physical performance and physical functioning. Data do not exist on these matters. Aims: General: To expand ~ in an efficient and cost-effective way - the database of the Chicago Heart Association (CHA) Study with new data to make a further major contribution in knowledge about the decades-long consequences of low risk (LR) present in young adulthood/early middle-age, particularly its relevance for achieving freedom in older age from non-invasively detectable subclinical CHD/CVD, inflammatory markers of CHD/CVD risk, and impairment of physical performance and functioning -- in both genders and across SES strata of varied ethnicity including people already long- lived (ages 75+). To achieve Aims (General and Specific), weighted random samples of the CHA cohort baseline ages 25-44 in 1967-73 - low risk (n=600) and not low risk (n=900) - are to be examined in 2006-2009 at ages 65-79. Specific Aims: Assess long-term relationship of baseline LR status (ages 25-44) with: 1) presence and extent of subclinical atherosclerotic disease at ages 65-79; 2) levels of CVD- related markers of inflammation at ages 65-79; 3) levels of objectively measured physical performance/function at ages 65-79. 4) Determine role of current subclinical atherosclerotic disease and inflammatory markers in accounting for associations of LR profile at younger age with physical performance/function at older age. Significance: The expected new data from the proposed research can serve to clarify and inform strategic priorities for attaining the two stipulated Healthy People 2010 primary goals, "increase quality and years of healthy life" and "eliminate health disparities."